Neurogene Revenue and Competitors

Location

#3864

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Neurogene's estimated annual revenue is currently $18M per year.(i)
  • Neurogene's estimated revenue per employee is $155,000
  • Neurogene's total funding is $184M.

Employee Data

  • Neurogene has 116 Employees.(i)
  • Neurogene grew their employee count by 17% last year.

Neurogene's People

NameTitleEmail/Phone
1
Founder & CEOReveal Email/Phone
2
VP Clinical and Translational Biomarker StrategyReveal Email/Phone
3
VP Regulatory AffairsReveal Email/Phone
4
Head ManufacturingReveal Email/Phone
5
SVP, Early Clinical and Translational ResearchReveal Email/Phone
6
SVP, Business OperationsReveal Email/Phone
7
Head Quality AssuranceReveal Email/Phone
8
SVP, Technical OperationsReveal Email/Phone
9
SVP, Clinical DevelopmentReveal Email/Phone
10
SVP, Regulatory Affairs, Quality Assurance, and Quality ControlReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-20%N/AN/A
#2
$6.7M438%N/AN/A
#3
$34.4M222-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.3M2-50%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$3.6M230%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

What Is Neurogene?

Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies. Although the human genome was sequenced for the first time nearly 20 years ago, the true genomics revolution is taking place now, providing us with the ability to radically alter rare, genetic disorders. At Neurogene, we are working to provide medicines to improve the lives of neurologically-impaired and developmentally-delayed children and their families. For children, our goal is simple: to enable them to have a healthier future. For their families, we want to make their lives better: when one family member is neurologically impaired, there is a heavy burden on caregivers ᅢᄁ¬ツᆲ¬タワ whether it is caring for an infant who will not live to see her third birthday, communicating with a son who doesnᅢᄁ¬ツᆲ¬トᄁt speak, or attempting to control a teenager in the throes of a self-injurious tantrum. We are building a team of passionate, driven individuals who envision a world in which all families have access to genetic medicines, even if the disorder is exceedingly rare. To learn more, please visit http://www.neurogene.com/careers/.

keywords:N/A

$184M

Total Funding

116

Number of Employees

$18M

Revenue (est)

17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Neurogene News

2022-03-30 - Wednesday's Child: 2-year-old Ivan will steal your heart

"Ivan has a rare neurogenetic spectrum disorder which requires that he has consistent care," Ursillo said. "The disorder that ivan has,...

2022-03-22 - Batten down for gene therapy testing as field hatches new ...

The recent start of Neurogene Inc.'s first-in-human trial testing NG-101 in ceroid lipofuscinosis type 5 (CLN5) Batten disease (BD) drew...

2020-12-16 - Neurogene Closes $115 Million Series B Financing

NEW YORK--(BUSINESS WIRE)--Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the completion of a $115 million Series B financing. The financing round was led by EcoR1 Capital, with participa ...

2019-02-12 - Neurogene Raises $68.5M in Series A Financing

Neurogene, Inc., a NYC-based company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, raised $68.5m in Series A financing. Investors included Samsara BioCapital, EcorR1 Capital, Cormorant Asset Management, Redmile Group and ...

2019-02-12 - Neurogene Raises $68.5 Million In Series A

NEW YORK--(BUSINESS WIRE)--Neurogene, Inc., a company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, today announced a $68.5 million Series A financing. Investors included Samsara BioCapital, EcorR1 Capital, Cormorant Asse ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$20.2M1167%N/A
#2
$16.2M116-19%N/A
#3
$31.3M116-1%N/A
#4
$23.8M116-13%N/A
#5
$20.9M1165%N/A